Adjunctive fecal microbiota transplantation in supportive oncology: Emerging indications and considerations in immunocompromised patients
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
FMT has gained enormous momentum in the treatment of acute inflammatory and infectious diseases. Despite an encouraging safety profile, FMT has been met with caution in the oncological setting due to perceived infectious risks in immunocompromised patients. Theoretical risks aside, the application of FMT in oncology may stand to benefit patients, via modulation of treatment efficacy and the mitigation of treatment complications. Here, we summarize most recent safety data of FMT in immunocompromised cohorts, including people with cancer, highlighting that FMT may actually provide protection against bacterial translocation via introduction of a diverse microbiome and restoration of epithelial defenses. We also discuss the emerging translational applications of FMT within supportive oncology, including the prevention and treatment of graft vs. host disease and sepsis, treatment of immunotherapy-induced colitis and restoration of the gut microbiome in survivors of childhood cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gut Microbiota from Twins Discordant for Obesity Modulate Metabolism in Mice
Ridaura, V. K., Faith, J. J., Rey, F. E., Cheng, J., Duncan, A. E., Kau, A. L., Griffin, N. W., Lombard, V., Henrissat, B., Bain, J. R., et al. (2013) · Science · doi:10.1126/science.1241214 · Cited by 3,788 · cited 1×
“Despite the encouraging safety record of FMT, there is risk of disease transmission from thedonor to recipient via stool, including infection, as well as immunological and metabolic disorders [21].”
Duodenal Infusion of Donor Feces for Recurrent Clostridium difficile
van Nood, E., Vrieze, A., Nieuwdorp, M., Fuentes, S., Zoetendal, E. G., de Vos, W. M., Visser, C. E., Kuijper, E. J., Bartelsman, J. F. W. M., Tijssen, J. G. P., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1205037 · Cited by 3,708 · cited 2×
“Since the landmark clinical FMT trial for recurrent CDI [4], regulations surrounding FMT have undergone many changes worldwide (Table 3), particularly reflected in the USA.”
BackgroundAnticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota
Vétizou, M., Pitt, J. M., Daillère, R., Lepage, P., Waldschmitt, N., Flament, C., Rusakiewicz, S., Routy, B., Roberti, M. P., Duong, C. P. M., et al. (2015) · Science · doi:10.1126/science.aad1329 · Cited by 3,488 · cited 1×
“Additionally, modulation of the gut microbiota via FMT from patients has been shown to alter antitumor immunity and response to immunotherapy in gnotobiotic mice (Table 2) [44].”
BackgroundChaput, N., Lepage, P., Coutzac, C., Soularue, E., Le Roux, K., Monot, C., Boselli, L., Routier, E., Cassard, L., Collins, M., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx108 · Cited by 1,310
European consensus conference on faecal microbiota transplantation in clinical practice
Cammarota, G., Ianiro, G., Tilg, H., Rajilić-Stojanović, M., Kump, P., Satokari, R., Sokol, H., Arkkila, P., Pintus, C., Hart, A., et al. (2017) · Gut · doi:10.1136/gutjnl-2016-313017 · Cited by 1,207 · cited 7×
“Comparable immunomodulatory effects have also been proposed to underpin the emerging efficacy of FMT in IBD, equilibrating aberrant immune signaling towards the indigenous microbiota [20].”
BackgroundInfluentialTaur, Y., Xavier, J. B., Lipuma, L., Ubeda, C., Goldberg, J., Gobourne, A., Lee, Y. J., Dubin, K. A., Socci, N. D., Viale, A., et al. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis580 · Cited by 1,020
Dubin, K., Callahan, M. K., Ren, B., Khanin, R., Viale, A., Ling, L., No, D., Gobourne, A., Littmann, E., Huttenhower, C., et al. (2016) · Nature Communications · doi:10.1038/ncomms10391 · Cited by 987 · cited 2×
“Certain bacterial signatures have been shown to associate with differential responses to immunotherapies [42,43], both in terms of treatment efficacy and toxicity.”
BackgroundGut microbiota modulation of chemotherapy efficacy and toxicity
Alexander, J. L., Wilson, I. D., Teare, J., Marchesi, J. R., Nicholson, J. K., & Kinross, J. M. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.20 · Cited by 970 · cited 1×
“Technological advances have facilitated a clearer mechanistic appreciation of the contribution of gut microbiota to GI toxicity in anti-cancer therapy [33,34], however dissecting the causative role for the microbiome in GI toxicity remains challenging.”
BackgroundFecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis
Wang, Y., Wiesnoski, D. H., Helmink, B. A., Gopalakrishnan, V., Choi, K., DuPont, H. L., Jiang, Z.-D., Abu-Sbeih, H., Sanchez, C. A., Chang, C.-C., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0238-9 · Cited by 740
Toll-like receptor 2 controls mucosal inflammation by regulating epithelial barrier function
Cario, E., Gerken, G., & Podolsky, D. K. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.02.056 · Cited by 697
Cited by
Gut-Microbiota-Derived Metabolites Maintain Gut and Systemic Immune Homeostasis
Wang, J., Zhu, N., Su, X., Gao, Y., & Yang, R. (2023) · Cells · doi:10.3390/cells12050793 · Cited by 588
The microbiome and gynaecological cancer development, prevention and therapy
Łaniewski, P., Ilhan, Z. E., & Herbst-Kralovetz, M. M. (2020) · Nature Reviews Urology · doi:10.1038/s41585-020-0286-z · Cited by 450
Fecal microbiota transplantation beyond Clostridioides difficile infections
Wortelboer, K., Nieuwdorp, M., & Herrema, H. (2019) · eBioMedicine · doi:10.1016/j.ebiom.2019.05.066 · Cited by 163
Gut Microbiota-Derived Short-Chain Fatty Acids: Impact on Cancer Treatment Response and Toxicities
Al-Qadami, G. H., Secombe, K. R., Subramaniam, C. B., Wardill, H. R., & Bowen, J. M. (2022) · Microorganisms · doi:10.3390/microorganisms10102048 · Cited by 162
Self-citationApplications of gut microbiota in patients with hematopoietic stem-cell transplantation
Yu, J., Sun, H., Cao, W., Han, L., Song, Y., Wan, D., & Jiang, Z. (2020) · Experimental Hematology & Oncology · doi:10.1186/s40164-020-00194-y · Cited by 25
Metadata
- Authors
- Wardill, H. R., Secombe, K. R., Bryant, R. V., Hazenberg, M. D., & Costello, S. P.
- Venue
- eBioMedicine
- Publisher
- Elsevier BV
- Published
- 2019-06
- Volume
- 44
- Pages
- 730-740
- ISSN
- 2352-3964 (ISSN-L)
- OpenAlex
- W2934603467
- Cited by
- 82
- References
- 17
- FWCI
- 3.01
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Adjunctive fecal microbiota transplantation in supportive oncology: Emerging indications and considerations in immunocompromised patients. https://app.cochat.ai/papers/10.1016/j.ebiom.2019.03.070
- The paper
- Wardill, H. R., Secombe, K. R., Bryant, R. V., Hazenberg, M. D., & Costello, S. P. (2019). Adjunctive fecal microbiota transplantation in supportive oncology: Emerging indications and considerations in immunocompromised patients. eBioMedicine. https://doi.org/10.1016/j.ebiom.2019.03.070
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.